Search all trials

Find therapies in clinical trials near you – page 2

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Fallopian tube cancer+2

Not yet recruiting

Registered drugNo placebo

Study on Bevacizumab Dose Equivalence for Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer Using Bevacizumab, Olaparib, Carboplatin, and Paclitaxel

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Fallopian tube cancer+1

Not yet recruiting

Registered drugNo placebo

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Fallopian tube cancer+2

Not recruiting

Registered drugNo placebo

Study of Relacorilant and Nab-Paclitaxel for Patients with Advanced, Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Relacorilant

Contact Research Centre

Fallopian tube cancer+4

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Brimonidine Tartrate

Contact Research Centre

Fallopian tube cancer+2

Not recruiting

Registered drugNo placebo

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Nemvaleukin Alfa

Contact Research Centre

Fallopian tube cancer+3

Not recruiting

Registered drugNo placebo

Study on Mirvetuximab Soravtansine and Carboplatin for Patients with Recurrent Ovarian Cancer Eligible for Platinum-Based Chemotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Fallopian tube cancer+2

Not recruiting

Registered drugNo placebo

Study of Pembrolizumab for Patients with Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Fallopian tube cancer+2

Not recruiting

Registered drugNo placebo

Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Fallopian tube cancer+2

Not recruiting

Registered drug

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

Fallopian tube cancer+2

Not recruiting

Registered drugNo placebo

Study on the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Sodium Thiosulfate for Ovarian Cancer Patients Undergoing Surgery

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cisplatin

Contact Research Centre

Fallopian tube cancer+2

Not recruiting

Registered drugNo placebo

Study on Carboplatin, Paclitaxel, Bevacizumab, and Rucaparib for Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Patients

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Fallopian tube cancer+2

Not recruiting

Investigational

Study Comparing Paclitaxel, Carboplatin, and Oregovomab with Paclitaxel, Carboplatin, and Placebo for Patients with Advanced Ovarian Cancer

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Oregovomab

Contact Research Centre

Find therapies in clinical trials near you – page 2

30 trials match your criteria

Fallopian tube cancer+2

Study on Bevacizumab Dose Equivalence for Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer Using Bevacizumab, Olaparib, Carboplatin, and Paclitaxel

Fallopian tube cancer+1

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian tube cancer+2

Study of Relacorilant and Nab-Paclitaxel for Patients with Advanced, Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Fallopian tube cancer+4

Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

Fallopian tube cancer+2

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Fallopian tube cancer+3

Study on Mirvetuximab Soravtansine and Carboplatin for Patients with Recurrent Ovarian Cancer Eligible for Platinum-Based Chemotherapy

Fallopian tube cancer+2

Study of Pembrolizumab for Patients with Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Fallopian tube cancer+2

Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

Fallopian tube cancer+2

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Fallopian tube cancer+2

Study on the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Sodium Thiosulfate for Ovarian Cancer Patients Undergoing Surgery

Fallopian tube cancer+2

Study on Carboplatin, Paclitaxel, Bevacizumab, and Rucaparib for Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Patients

Fallopian tube cancer+2

Study Comparing Paclitaxel, Carboplatin, and Oregovomab with Paclitaxel, Carboplatin, and Placebo for Patients with Advanced Ovarian Cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.